

MEDICAL ONCOLOGY

PAPER-III

Time: 3 hours
Max. Marks:100

MED.ONCO./D/20/17/III

Important Instructions:

- *You are provided with 5 answer sheet booklets. Each individual answer sheet booklet consists of 10 pages excluding the covering jackets.*
- *Answers to all the questions must be attempted within these 5 answer sheet booklets which must be later tagged together at the end of the exam.*
- *No additional supplementary answer sheet booklet will be provided.*
- *Attempt all questions in order.*
- *Each question carries 10 marks.*
- *Read the question carefully and answer to the point neatly and legibly.*
- *Do not leave any blank pages between two answers.*
- *Indicate the question number correctly for the answer in the margin space.*
- *Answer all the parts of a single question together.*
- *Start the answer to a question on a fresh page or leave adequate space between two answers.*
- *Draw table/diagrams/flowcharts wherever appropriate.*

Write short notes on:

1. a) A 50-year-old man, with no known comorbidities, has been diagnosed with metastatic adenocarcinoma of pancreas. He also has deep vein thrombosis of the right leg and severe back pain. Describe the management of this patient. 6+4
b) Systemic therapy of advanced hepatocellular carcinoma.
2. a) Discuss the prognostic factors in pediatric Ewing's sarcoma. 4+6
b) A 14-year-old adolescent boy has been evaluated for a left thigh swelling. Local MRI imaging and biopsy reveal Ewing's sarcoma of left femur. As an algorithmic approach, describe the further evaluation and multidisciplinary treatment of this patient, including relevant treatment protocol(s) in brief.
3. a) A 54-year-old post-menopausal woman presents with a left breast lump and palpable left axillary nodes. Biopsy from lump is suggestive of infiltrating ductal carcinoma. Describe an algorithmic approach to the multidisciplinary management of locally advanced breast cancer in this patient. 6+4
b) Role of breast conservation in the treatment of breast cancers.
4. a) Role of molecular genetics in pediatric gliomas. 5+5
b) A 56-year-old woman, with no known comorbidities, has been diagnosed with a glioblastoma multiform of the right parietal lobe of brain. Describe an algorithmic approach to the multidisciplinary management of this patient.

P.T.O.

MEDICAL ONCOLOGY
PAPER-III

5. A 38-year-old man with relapsed refractory diffuse large B-cell Lymphoma after 3 lines of therapy has been advised Chimeric Antigen Receptor (CAR) T-Cell therapy. 6+4
a) Describe the basic principles, manufacture and clinical pathway of CAR-T Cell therapy.
b) Post CAR-T cell therapy, how will you grade and manage cytokine release syndrome?
6. a) Concepts of treatment milestones in chronic myeloid leukemia and the role of a treatment-free remission approach. 5+5
b) Role of bone marrow transplantation in post TKI era.
7. a) Supportive care and rehabilitation approach to a patient receiving chemoradiation for head and neck cancer. 5+5
b) Indications and approach to neoadjuvant treatment of rectal cancer.
8. a) Management of patient(s) with locally recurrent cancer of uterine cervix. 5+5
b) Describe a treatment algorithm for the initial systemic therapy of advanced/ metastatic renal cancer and discuss the role of molecularly targeted agents as monotherapy or combination therapy in this scenario.
9. A 62-year-old male with a 10-pack-year history of smoking and persistent cough has been diagnosed with adenocarcinoma lung and staged cT2N1M0 by PET-CT scan. 2+6+2
a) Discuss the indications and approaches for invasive mediastinal staging in lung cancer.
b) Discuss the curative management of a pathologically confirmed N2 disease in this scenario of lung cancer.
c) The family states that the patient was planning to quit smoking. How will you address smoking cessation in a patient?
10. a) Define Graft-versus-Host Disease (GVHD) and discuss the severity grading of acute GVHD. 4+3+3
b) Discuss the various regimens used in acute GVHD prophylaxis of allogeneic hematopoietic cell transplantation.
c) Discuss the side-effect profile of commonly used calcineurin inhibitors.
